Navigation Links
Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging,Growth Opportunities Conference

MALVERN, Pa., June 28, 2007 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc. today announced that Mr. Armando Anido, Chief Executive Officer and President, and Mr. Jim Fickenscher, Chief Financial Officer, will participate in the 2007 CEUT Emerging Growth Opportunities Conference to be held July 10 through July 12, 2007 at the Mandarin Oriental Hotel in New York City. Mr. Anido is scheduled to present an overview of the Company and its product pipeline at 4:30 PM Eastern Time on Wednesday, July 11, 2007.

To listen to the audio web cast of the presentation during or after the event, please visit: http://www.auxilium.com. The replay will be available for 90 days after the event.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. AA4500, an injectable collagenase enzyme, is in phase III of development for the treatment of Dupuytren's contracture and is in phase II of development for the treatment of Peyronie's disease and Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) is in phase I of development. The Company is currently seeking a partner to further develop this product candidate. Auxilium has two pain products using its transmucosal film delivery system in pre-clinical development. Auxilium has rights to six additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system, and options to all indications using AA4500 for non-topical formulations. For additional info
'"/>




Page: 1 2 3

Related medicine technology :

1. Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

Post Your Comments:
(Date:11/19/2009)...and, Nov. 19 Warner Chilcott plc (... previously announced secondary offering of 20,000...ic of $22.25 per share. The selling shareholders ...s, DLJ Merchant Banking, J.P. Morgan Partners (adv...L.P., certain other institutional investors and me...
(Date:11/19/2009)...W, Calif., Nov. 19 Alexz... today that its corporate presentation will be web...lth Care Conference on Wednesday, December 2, 2009... be webcast from The New York Palace Hotel in New ...za President and CEO. ,, To access the live p...
(Date:11/19/2009)...International Internet Week of Action ,, SILVE...The U.S. Food and Drug Administration today comple... called the International Internet Week of Action ... medical products. ,, (Logo: http://www.newsco... the effort, the FDA,s Office of Criminal Investig...
Breaking Medicine Technology:Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2CareFusion Launches New Brand Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 50517 1CareFusion Launches New Brand Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 50517 2CareFusion Launches New Brand Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 50517 3BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday July 30 at 5 3A00 p m ET 2823 3A00 CET 29 50515 1BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday July 30 at 5 3A00 p m ET 2823 3A00 CET 29 50515 2Air Force Chief Master Sergeant Rod McKinley 28U S Air Force Retired 29 Joins MicroTech as Vice President of Strategic Partnerships 12870 1Air Force Chief Master Sergeant Rod McKinley 28U S Air Force Retired 29 Joins MicroTech as Vice President of Strategic Partnerships 12870 2Air Force Chief Master Sergeant Rod McKinley 28U S Air Force Retired 29 Joins MicroTech as Vice President of Strategic Partnerships 12870 3
...ight for physicians, NATICK, Mass. and WASHINGTON...SX ) today announced results from an analysis,of t...nsored by the,Cardiovascular Research Foundation (...tific and The Medicines Company (Nasdaq: MDCO ) i... the TAXUS(R) Express2(TM),Paclitaxel-Eluting Coro...
...safety and efficacy outcomes for two thirds ...ass. and WASHINGTON, Oct. 14 Boston,Scientific Co...eft main and,three-vessel disease subset data from...coronary intervention (PCI) using the TAXUS(R) Exp... to contemporary coronary artery,bypass graft (CAB...
Other Medicine Technology:HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients 2HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients 3HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients 4SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery 2SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery 3SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery 4SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery 5
(Date:11/20/2009)...ially adding to preemie delivery rate, experts say... Recent reports show that the rate of preterm deli...ow, a new study suggests one reason why: Many wome...birth in the first place. , About one-quarter o...aby born at 34 to 36 weeks of gestation to be full...
(Date:11/20/2009)... against the new breast cancer recommendations rel.... These guidelines may be cost-effective, but they...g to be safe than sorry? , ...commendations, published in the current issue of t...storm in the medical community. Major medical cent...
(Date:11/20/2009)...Newswire/ -- California minority advocacy groups i...ll/Las Memorias, Latina Breast Cancer Agency, Blac... Medicine Foundation today sent a letter to Blue S...nsider harmful and discriminatory coverage policie...lls for an end to the practice of step therapy, wh...
(Date:11/20/2009)...USNewswire/ -- The US government reported Monday t... food to eat. This startling statistic highlights...aging into poverty. "Forced retirements, layoffs,...ve incomes that no longer cover the basic expenses...articularly vulnerable," said Kate White Executive...
(Date:11/20/2009)...g; is pleased to announce its agreement with VHA I...ultispecialty physicians for locum tenens (tempora... placement. , Alpharetta,...e is pleased to announce its agreement with VHA In...ltispecialty physicians for locum tenens (temporar...
Breaking Medicine News(10 mins):Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 2Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 3Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 3Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 4Health News:VHA Names Jackson Healthcare as Preferred Physician Staffing Vendor 2Health News:VHA Names Jackson Healthcare as Preferred Physician Staffing Vendor 3
...ss surgery can restore function for obese males, s... News) -- The more obese a man, the greater his ho...tudy finds. , On the up side, the study,s authors ...be associated with infertility, but we wanted to k...
...rch 3 Important deadlines are approaching for cla...elated to the average wholesale prices of certain ...rt for the District of Massachusetts granted preli...CV-12257-PBS, MDL No. 1456, plaintiffs claimed tha...
...ennett is Named as the President and CEO of the Ne...lo Pharmaceutical, a privately held specialty phar... establishing a Canadian subsidiary to be called H...e and distribution of branded pharmaceutical produ...
... March 3 Stephen Bablitch, a former top official ...ief executive of Blue Cross and Blue Shield of Wis...adership team. , , (Photo: http://www.newscom.co...he Milwaukee office of the law firm Quarles & ...
...secutive Year DaVita Ranks as One of the World,s M...ch 3 DaVita Inc., a leading provider of kidney ca... Magazine as one of the top health care facilities...ervices. Overall, the company ranked 2nd in the He...
...s from The University of Nottingham will study the...art of a study investigating treatments for people...(MS). , It is thought that hookworms may play a r...0, three-year project funded by the MS Society, ai...
Other Medicine News:Health News:Men's Sex Lives May Suffer as Waistlines Expand 2Health News:Important Deadlines Near for $21 Million Class Action Settlement That Provides Consumers With Money Back for Over 200 Prescription Drugs 2Health News:Halo Pharmaceutical Launches a Branded Product Marketing Company in Canada 2Health News:Stephen Bablitch to Join Aurora Health Care's Senior Leadership Team 2Health News:Stephen Bablitch to Join Aurora Health Care's Senior Leadership Team 3Health News:FORTUNE Magazine Ranks DaVita #1 Health Care Medical Facility in Innovation, Investment and Quality 2Health News:Hookworms in MS trial 2
...w standard in the field of hammertoe implants with...al grade silicone, these durable and lasting impla...lexibility while maintaining correct toe length an...iffnesses. Lengths are determined by the surgeon f...
...lant (KGTI) system offers the latest technology an...lant system is anatomically designed and restores ...nced reconstructive device for the first metatarso...stem consists of anatomically and biomechanically ...
...as been approved for use as an adjunctive therapy ...d adolescents over 12 years of age with partial on...medications. This indication is based on outcomes ...ured as median seizure reduction, was observed in ...
Epidural Spinal Electrodes
Medicine Products: